Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
出版年份 2022 全文链接
标题
Simultaneous glutamine metabolism and PD-L1 inhibition to enhance suppression of triple-negative breast cancer
作者
关键词
-
出版物
JOURNAL OF NANOBIOTECHNOLOGY
Volume 20, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2022-05-06
DOI
10.1186/s12951-022-01424-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis
- (2021) Michal Sternschuss et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Cell-programmed nutrient partitioning in the tumour microenvironment
- (2021) Bradley I. Reinfeld et al. NATURE
- Tissue-Resident Memory-Like CD8+ T Cells Exhibit Heterogeneous Characteristics in Tuberculous Pleural Effusion
- (2021) Sifei Yu et al. Journal of Immunology Research
- Immunotherapy in Breast Cancer: When, How, and What Challenges?
- (2021) Beatriz Henriques et al. Biomedicines
- Targeting pulmonary tumor microenvironment with CXCR4-inhibiting nanocomplex to enhance anti–PD-L1 immunotherapy
- (2020) Zhaoting Li et al. Science Advances
- Recent advances of two-dimensional materials in smart drug delivery nano-systems
- (2020) Hua Zhang et al. Bioactive Materials
- Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer
- (2020) Deanna N. Edwards et al. JOURNAL OF CLINICAL INVESTIGATION
- Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion
- (2019) Robert D. Leone et al. SCIENCE
- Enhanced glutamine uptake influences composition of immune cell infiltrates in breast cancer
- (2019) Rokaya El Ansari et al. BRITISH JOURNAL OF CANCER
- Pharmacological blockade of ASCT2-dependent glutamine transport leads to antitumor efficacy in preclinical models
- (2018) Michael L Schulte et al. NATURE MEDICINE
- Disruption of Amino Acid Homeostasis by Novel ASCT2 Inhibitors Involves Multiple Targets
- (2018) Angelika Bröer et al. Frontiers in Pharmacology
- We're Not “DON” Yet: Optimal Dosing and Prodrug Delivery of6-Diazo-5-oxo-L-norleucine
- (2018) Kathryn M. Lemberg et al. MOLECULAR CANCER THERAPEUTICS
- Emerging Cellular Therapies for Cancer
- (2018) Sonia Guedan et al. Annual Review of Immunology
- Distinct Regulation of Th17 and Th1 Cell Differentiation by Glutaminase-Dependent Metabolism
- (2018) Marc O. Johnson et al. CELL
- Glutamine: Metabolism and Immune Function, Supplementation and Clinical Translation
- (2018) Vinicius Cruzat et al. Nutrients
- The Smart Drug Delivery System and Its Clinical Potential
- (2016) Dong Liu et al. Theranostics
- Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes
- (2016) Sasha E. Stanton et al. JAMA Oncology
- TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer
- (2015) Steven J. Isakoff et al. JOURNAL OF CLINICAL ONCOLOGY
- ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer
- (2015) M van Geldermalsen et al. ONCOGENE
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer
- (2014) M. D. Burstein et al. CLINICAL CANCER RESEARCH
- Concurrent interaction of DCs with CD4+and CD8+T cells improves secondary CTL expansion: It takes three to tango
- (2014) Stefanie Hoyer et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Inflammatory T Cell Responses Rely on Amino Acid Transporter ASCT2 Facilitation of Glutamine Uptake and mTORC1 Kinase Activation
- (2014) Mako Nakaya et al. IMMUNITY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search